SCHEMBL7683385

SCHEMBL7683385

CC(C)c1c(C(=O)Nc2ccc(O)cc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H]1C[C@H](CC(=O)OC(C)(C)C)OC(C)(C)O1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLCO1B1 Q9Y6L6 4/20 0.63
HMGCR P04035 4/20 0.63
ABCB1 P08183 1/20 0.63
ABCC2 Q92887 1/20 0.63
ABCB11 O95342 3/20 0.49
HDAC1 Q13547 2/20 0.49
HDAC2 Q92769 2/20 0.49
HDAC6 Q9UBN7 2/20 0.49
NR1I2 O75469 1/20 0.49
RHOC P08134 1/20 0.49
CYP3A4 P08684 1/20 0.49
THRB P10828 1/20 0.49
NR1H4 Q96RI1 1/20 0.49
ABCG2 Q9UNQ0 1/20 0.49
PDE6D O43924 3/20 0.48
ABCC3 O15438 2/20 0.48
ABCC4 O15439 2/20 0.48
SLCO1B3 Q9NPD5 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23636413 0.99 SLCO1B1 (0.62) SLCO1B1HMGCRABCB1ABCC2ABCB11
SCHEMBL6761321 0.97 SLCO1B1 (0.66) SLCO1B1HMGCRABCB1ABCC2ABCB11
SCHEMBL6761324 0.97 SLCO1B1 (0.66) SLCO1B1HMGCRABCB1ABCC2ABCB11
SCHEMBL583215 0.97 SLCO1B1 (0.67) SLCO1B1HMGCRABCB1ABCC2ABCB11
SCHEMBL12238539 0.97 SLCO1B1 (0.67) SLCO1B1HMGCRABCB1ABCC2ABCB11
SCHEMBL17987930 0.97 SLCO1B1 (0.67) SLCO1B1HMGCRABCB1ABCC2ABCB11
SCHEMBL2286479 0.97 SLCO1B1 (0.67) SLCO1B1HMGCRABCB1ABCC2ABCB11
SCHEMBL28548964 0.97 SLCO1B1 (0.67) SLCO1B1HMGCRABCB1ABCC2ABCB11
SCHEMBL28551907 0.97 SLCO1B1 (0.67) SLCO1B1HMGCRABCB1ABCC2ABCB11
SCHEMBL6769207 0.96 SLCO1B1 (0.65) SLCO1B1HMGCRABCB1ABCC2ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11066391-B1 Atorvastatin derived HMG-CoA reductase degradation inducing compound UPPTHERA (KR) 2021-07-20 US disclosed
US-6355810-B1 TREATMENT AND PREVENTION OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA, ATHEROSCLEROSIS ADVANCED MEDICINE, INC. 2002-03-12 US disclosed
EP-1083894-A1 MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE Advanced Medicine, Inc. (US) 2001-03-21 EP disclosed
WO-1999063994-A9 MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE ADVANCED MEDICINE INC (US) 2000-07-27 WO disclosed
WO-1999063994-A1 MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE ADVANCED MEDICINE, INC. (US) 1999-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066391-B1 Atorvastatin derived HMG-CoA reductase degradation inducing compound HMGCR, LDLR, HMGB2 SLCO1B1 2676/4885HMGCR 1/4885ABCB1 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.